ACIP updates adult vaccination recommendations, allowing Tdap or Td in more scenarios

The Advisory Committee on Immunization Practices (ACIP) has updated recommendations for adult vaccination in the United States. The guidance addresses the use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine compared to tetanus and diphtheria toxoids (Td) vaccine in adult populations. Study type, phase, sample size, and follow-up duration were not reported in the available information.

The main update involves increased flexibility in vaccine selection. In three specific scenarios where only Td vaccine had been previously recommended, clinicians may now consider either Tdap or Td vaccines. The recommendations also maintain that tetanus booster doses should be administered every 10 years for all adults. No specific effect sizes, absolute numbers, or statistical measures were reported for these recommendation changes.

Safety and tolerability data for the vaccines were not reported in this recommendation update. The publication did not include information on adverse events, serious adverse events, or discontinuation rates. Limitations of the available information include the absence of details about the evidence review process that informed these recommendations and lack of reported conflicts of interest or funding sources.

For clinical practice, these updated recommendations provide clinicians with more options when vaccinating adults against tetanus, diphtheria, and pertussis. The guidance represents an evolution in immunization strategy rather than a complete overhaul, maintaining the core recommendation for decennial tetanus boosters. Healthcare providers should review the complete ACIP guidance for specific implementation details and scenario definitions.